FDA approves colon cancer screening test
The U.S. Food and Drug Administration (FDA) has approved a new blood test called SimpleScreen CRC for early detection of colon and rectal cancer in adults over the age of 45 in moderate-risk groups. The test relies on analyzing genetic changes in the patient's blood and demonstrates an accuracy of up to 80% in detecting affected cases and 90% in negative results, based on a clinical study involving more than 48,000 participants. Despite its effectiveness, the test does not replace colonoscopy, which remains the gold standard for cancer detection, and is primarily recommended for individuals who refuse traditional screening methods.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)